Growing our Mission to Help People with ITP
Often called an “invisible disease,” Immune Thrombocytopenia (ITP) is a rare autoimmune disorder characterized by immunoglobulin G (IgG) antibodies that attack and destroy healthy blood cells. Primary ITP can cause spontaneous bruising, extreme fatigue and bleeding, negatively impacting people both personally and professionally. Ten in every 100,000 people across the world have ITP, and current treatment options are invasive, time-consuming and don’t work for everyone.
To help improve the lives of people with this severe, chronic disease, UCB is proud to partner with the global ITP and hematology communities to make a positive impact. As part of this mission, we have expanded our clinical development efforts in ITP and have new research to share at the 61st American Society of Hematology (ASH) annual meeting from December 7-10, 2019 in Orlando, Florida.
In an oral presentation at ASH, UCB will showcase final results from our Phase II clinical study of a new potential treatment for ITP. The study assessed the safety, tolerability and efficacy of injectable rozanolixizumab (rozimab), a biologic medicine that targets the neonatal Fc receptor (FcRn) pathway.
The growing body of rozimab data, which includes other immunoglobulin G autoantibody-mediated diseases such as myasthenia gravis, reaffirm our commitment to deliver solutions to people who have few options. We’re hopeful the science behind rozimab, combined with our focus on making a positive impact that people with these diseases will truly value, will enable us to transform the overall treatment experience.
To learn more about ITP, click here.